APO Research
Talk to an analyst

APO RESEARCH · REPORT

Plasmid DNA CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Plasmid DNA CDMO Service Market Analysis and Forecast 2026-2032

5 June 2026206 pages

Choose your research edition.

Industry ResearchPlasmid DNA CDMO Service Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Plasmid DNA CDMO Service Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Plasmid DNA CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Plasmid DNA CDMO Service Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Plasmid DNA CDMO Service Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Plasmid DNA CDMO Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Plasmid DNA CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Plasmid DNA CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Plasmid DNA CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Plasmid DNA CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Plasmid DNA CDMO Service include Creative Biogene, AGC Biologics, Biovian, GenScript ProBio, Charles River Laboratories, PackGene, Catalent Biologics, Patheon and Mycenax Biotech Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Plasmid DNA CDMO Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Plasmid DNA CDMO Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Plasmid DNA CDMO Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Plasmid DNA CDMO Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Plasmid DNA CDMO Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Plasmid DNA CDMO Service revenue, projected growth trends, production technology, application and end-user industry.

Plasmid DNA CDMO Service Segment by Company

Creative Biogene

AGC Biologics

Biovian

GenScript ProBio

Charles River Laboratories

PackGene

Catalent Biologics

Patheon

Mycenax Biotech Inc

VGXI

Esco Aster

Eurogentec

53Biologics

SK pharmteco

Cytovance Biologics

Aldevron

Bionova Scientific

Plasmid DNA CDMO Service Segment by Type

Research Grade

Commercial Grade

GMP Grade

Others

Plasmid DNA CDMO Service Segment by Application

Preclinical

Clinical

Commercial

Plasmid DNA CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasmid DNA CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Plasmid DNA CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasmid DNA CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Plasmid DNA CDMO Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Plasmid DNA CDMO Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Plasmid DNA CDMO Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Plasmid DNA CDMO Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Research Grade Major Player Table 3. Commercial Grade Major Player Table 4. GMP Grade Major Player Table 5. Others Major Player Table 6. Global Plasmid DNA CDMO Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Preclinical Major Player Table 8. Clinical Major Player Table 9. Commercial Major Player Table 10. Plasmid DNA CDMO Service Industry Trends Table 11. Plasmid DNA CDMO Service Industry Drivers Table 12. Plasmid DNA CDMO Service Industry Opportunities and Challenges Table 13. Plasmid DNA CDMO Service Industry Restraints Table 14. Global Plasmid DNA CDMO Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Plasmid DNA CDMO Service Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Plasmid DNA CDMO Service Market Share by Region (2021-2026) Table 17. Global Plasmid DNA CDMO Service Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Plasmid DNA CDMO Service Market Share by Region (2027-2032) Table 19. Global Plasmid DNA CDMO Service Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Plasmid DNA CDMO Service Revenue Market Share by Players (2021-2026) Table 21. Global Plasmid DNA CDMO Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Plasmid DNA CDMO Service Key Players Headquarters & Area Served Table 23. Global Plasmid DNA CDMO Service Players, Product Type & Application Table 24. Global Plasmid DNA CDMO Service Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Plasmid DNA CDMO Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Plasmid DNA CDMO Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Plasmid DNA CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Plasmid DNA CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Plasmid DNA CDMO Service Revenue Market Share by Type (2021-2026) Table 31. Global Plasmid DNA CDMO Service Revenue Market Share by Type (2027-2032) Table 32. Global Plasmid DNA CDMO Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Plasmid DNA CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Plasmid DNA CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Plasmid DNA CDMO Service Revenue Market Share by Application (2021-2026) Table 36. Global Plasmid DNA CDMO Service Revenue Market Share by Application (2027-2032) Table 37. Creative Biogene Company Information Table 38. Creative Biogene Business Overview Table 39. Creative Biogene Plasmid DNA CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Creative Biogene Plasmid DNA CDMO Service Product Portfolio Table 41. Creative Biogene Recent Development Table 42. AGC Biologics Company Information Table 43. AGC Biologics Business Overview Table 44. AGC Biologics Plasmid DNA CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. AGC Biologics Plasmid DNA CDMO Service Product Portfolio Table 46. AGC Biologics Recent Development Table 47. Biovian Company Information Table 48. Biovian Business Overview Table 49. Biovian Plasmid DNA CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Biovian Plasmid DNA CDMO Service Product Portfolio Table 51. Biovian Recent Development Table 52. GenScript ProBio Company Information Table 53. GenScript ProBio Business Overview Table 54. GenScript ProBio Plasmid DNA CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. GenScript ProBio Plasmid DNA CDMO Service Product Portfolio Table 56. GenScript ProBio Recent Development Table 57. Charles River Laboratories Company Information Table 58. Charles River Laboratories Business Overview Table 59. Charles River Laboratories Plasmid DNA CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Charles River Laboratories Plasmid DNA CDMO Service Product Portfolio Table 61. Charles River Laboratories Recent Development Table 62. PackGene Company Information Table 63. PackGene Business Overview Table 64. PackGene Plasmid DNA CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. PackGene Plasmid DNA CDMO Service Product Portfolio Table 66. PackGene Recent Development Table 67. Catalent Biologics Company Information Table 68. Catalent Biologics Business Overview Table 69. Catalent Biologics Plasmid DNA CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Catalent Biologics Plasmid DNA CDMO Service Product Portfolio Table 71. Catalent Biologics Recent Development Table 72. Patheon Company Information Table 73. Patheon Business Overview Table 74. Patheon Plasmid DNA CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Patheon Plasmid DNA CDMO Service Product Portfolio Table 76. Patheon Recent Development Table 77. Mycenax Biotech Inc Company Information Table 78. Mycenax Biotech Inc Business Overview Table 79. Mycenax Biotech Inc Plasmid DNA CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Mycenax Biotech Inc Plasmid DNA CDMO Service Product Portfolio Table 81. Mycenax Biotech Inc Recent Development Table 82. VGXI Company Information Table 83. VGXI Business Overview Table 84. VGXI Plasmid DNA CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. VGXI Plasmid DNA CDMO Service Product Portfolio Table 86. VGXI Recent Development Table 87. Esco Aster Company Information Table 88. Esco Aster Business Overview Table 89. Esco Aster Plasmid DNA CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Esco Aster Plasmid DNA CDMO Service Product Portfolio Table 91. Esco Aster Recent Development Table 92. Eurogentec Company Information Table 93. Eurogentec Business Overview Table 94. Eurogentec Plasmid DNA CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Eurogentec Plasmid DNA CDMO Service Product Portfolio Table 96. Eurogentec Recent Development Table 97. 53Biologics Company Information Table 98. 53Biologics Business Overview Table 99. 53Biologics Plasmid DNA CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. 53Biologics Plasmid DNA CDMO Service Product Portfolio Table 101. 53Biologics Recent Development Table 102. SK pharmteco Company Information Table 103. SK pharmteco Business Overview Table 104. SK pharmteco Plasmid DNA CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. SK pharmteco Plasmid DNA CDMO Service Product Portfolio Table 106. SK pharmteco Recent Development Table 107. Cytovance Biologics Company Information Table 108. Cytovance Biologics Business Overview Table 109. Cytovance Biologics Plasmid DNA CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Cytovance Biologics Plasmid DNA CDMO Service Product Portfolio Table 111. Cytovance Biologics Recent Development Table 112. Aldevron Company Information Table 113. Aldevron Business Overview Table 114. Aldevron Plasmid DNA CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Aldevron Plasmid DNA CDMO Service Product Portfolio Table 116. Aldevron Recent Development Table 117. Bionova Scientific Company Information Table 118. Bionova Scientific Business Overview Table 119. Bionova Scientific Plasmid DNA CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Bionova Scientific Plasmid DNA CDMO Service Product Portfolio Table 121. Bionova Scientific Recent Development Table 122. North America Plasmid DNA CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 123. North America Plasmid DNA CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 124. North America Plasmid DNA CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 125. North America Plasmid DNA CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 126. North America Plasmid DNA CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. North America Plasmid DNA CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 128. North America Plasmid DNA CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 129. Europe Plasmid DNA CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 130. Europe Plasmid DNA CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 131. Europe Plasmid DNA CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 132. Europe Plasmid DNA CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 133. Europe Plasmid DNA CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Europe Plasmid DNA CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 135. Europe Plasmid DNA CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 136. China Plasmid DNA CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 137. China Plasmid DNA CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 138. China Plasmid DNA CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 139. China Plasmid DNA CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 140. Asia Plasmid DNA CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 141. Asia Plasmid DNA CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 142. Asia Plasmid DNA CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 143. Asia Plasmid DNA CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 144. Asia Plasmid DNA CDMO Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Asia Plasmid DNA CDMO Service Revenue by Region (US$ Million) & (2021-2026) Table 146. Asia Plasmid DNA CDMO Service Revenue by Region (US$ Million) & (2027-2032) Table 147. SAMEA Plasmid DNA CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 148. SAMEA Plasmid DNA CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 149. SAMEA Plasmid DNA CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 150. SAMEA Plasmid DNA CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 151. SAMEA Plasmid DNA CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. SAMEA Plasmid DNA CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 153. SAMEA Plasmid DNA CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Plasmid DNA CDMO Service Image Figure 2. Global Plasmid DNA CDMO Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Plasmid DNA CDMO Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Research Grade Image Figure 5. Commercial Grade Image Figure 6. GMP Grade Image Figure 7. Others Image Figure 8. Global Plasmid DNA CDMO Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Plasmid DNA CDMO Service Market Size Share 2021 VS 2025 VS 2032 Figure 10. Preclinical Image Figure 11. Clinical Image Figure 12. Commercial Image Figure 13. Global Plasmid DNA CDMO Service Market Size (US$ Million) & (2021-2032) Figure 14. Global Plasmid DNA CDMO Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Plasmid DNA CDMO Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Plasmid DNA CDMO Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Plasmid DNA CDMO Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Plasmid DNA CDMO Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Plasmid DNA CDMO Service Revenue Market Share by Type (2021-2032) Figure 21. Global Plasmid DNA CDMO Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Plasmid DNA CDMO Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Plasmid DNA CDMO Service Revenue Market Share by Application (2021-2032) Figure 24. North America Plasmid DNA CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Plasmid DNA CDMO Service Revenue Share by Type (2021-2032) Figure 26. North America Plasmid DNA CDMO Service Revenue Share by Application (2021-2032) Figure 27. North America Plasmid DNA CDMO Service Revenue Share by Country (2021-2032) Figure 28. United States Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Plasmid DNA CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Plasmid DNA CDMO Service Revenue Share by Type (2021-2032) Figure 33. Europe Plasmid DNA CDMO Service Revenue Share by Application (2021-2032) Figure 34. Europe Plasmid DNA CDMO Service Revenue Share by Country (2021-2032) Figure 35. Germany Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Plasmid DNA CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Plasmid DNA CDMO Service Revenue Share by Type (2021-2032) Figure 45. China Plasmid DNA CDMO Service Revenue Share by Application (2021-2032) Figure 46. Asia Plasmid DNA CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Plasmid DNA CDMO Service Revenue Share by Type (2021-2032) Figure 48. Asia Plasmid DNA CDMO Service Revenue Share by Application (2021-2032) Figure 49. Asia Plasmid DNA CDMO Service Revenue Share by Region (2021-2032) Figure 50. Japan Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Plasmid DNA CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Plasmid DNA CDMO Service Revenue Share by Type (2021-2032) Figure 58. SAMEA Plasmid DNA CDMO Service Revenue Share by Application (2021-2032) Figure 59. SAMEA Plasmid DNA CDMO Service Revenue Share by Country (2021-2032) Figure 60. Brazil Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Plasmid DNA CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Research Grade
  • Commercial Grade
  • GMP Grade
  • Others
Applications
  • Preclinical
  • Clinical
  • Commercial
Companies covered
  • Creative Biogene
  • AGC Biologics
  • Biovian
  • GenScript ProBio
  • Charles River Laboratories
  • PackGene
  • Catalent Biologics
  • Patheon
  • Mycenax Biotech Inc
  • VGXI
  • Esco Aster
  • Eurogentec
  • 53Biologics
  • SK pharmteco
  • Cytovance Biologics
  • Aldevron
  • Bionova Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Plasmid DNA CDMO Service Market by Type
  3. 1.2.1 Global Plasmid DNA CDMO Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Research Grade
  5. 1.2.3 Commercial Grade
  6. 1.2.4 GMP Grade
  7. 1.2.5 Others
  8. 1.3 Plasmid DNA CDMO Service Market by Application
  9. 1.3.1 Global Plasmid DNA CDMO Service Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Preclinical
  11. 1.3.3 Clinical
  12. 1.3.4 Commercial
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Plasmid DNA CDMO Service Market Dynamics
  1. 2.1 Plasmid DNA CDMO Service Industry Trends
  2. 2.2 Plasmid DNA CDMO Service Industry Drivers
  3. 2.3 Plasmid DNA CDMO Service Industry Opportunities and Challenges
  4. 2.4 Plasmid DNA CDMO Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Plasmid DNA CDMO Service Market Perspective (2021-2032)
  2. 3.2 Global Plasmid DNA CDMO Service Growth Trends by Region
  3. 3.2.1 Global Plasmid DNA CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Plasmid DNA CDMO Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Plasmid DNA CDMO Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Plasmid DNA CDMO Service Revenue by Players
  2. 4.1.1 Global Plasmid DNA CDMO Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Plasmid DNA CDMO Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Plasmid DNA CDMO Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Plasmid DNA CDMO Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Plasmid DNA CDMO Service Key Players Headquarters & Area Served
  7. 4.4 Global Plasmid DNA CDMO Service Players, Product Type & Application
  8. 4.5 Global Plasmid DNA CDMO Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Plasmid DNA CDMO Service Market CR5 and HHI
  11. 4.6.3 2025 Plasmid DNA CDMO Service Tier 1, Tier 2, and Tier 3
5 Plasmid DNA CDMO Service Market Size by Type
  1. 5.1 Global Plasmid DNA CDMO Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Plasmid DNA CDMO Service Revenue by Type (2021-2032)
  3. 5.3 Global Plasmid DNA CDMO Service Revenue Market Share by Type (2021-2032)
6 Plasmid DNA CDMO Service Market Size by Application
  1. 6.1 Global Plasmid DNA CDMO Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Plasmid DNA CDMO Service Revenue by Application (2021-2032)
  3. 6.3 Global Plasmid DNA CDMO Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Creative Biogene
  2. 7.1.1 Creative Biogene Company Information
  3. 7.1.2 Creative Biogene Business Overview
  4. 7.1.3 Creative Biogene Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Creative Biogene Plasmid DNA CDMO Service Product Portfolio
  6. 7.1.5 Creative Biogene Recent Developments
  7. 7.2 AGC Biologics
  8. 7.2.1 AGC Biologics Company Information
  9. 7.2.2 AGC Biologics Business Overview
  10. 7.2.3 AGC Biologics Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 AGC Biologics Plasmid DNA CDMO Service Product Portfolio
  12. 7.2.5 AGC Biologics Recent Developments
  13. 7.3 Biovian
  14. 7.3.1 Biovian Company Information
  15. 7.3.2 Biovian Business Overview
  16. 7.3.3 Biovian Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Biovian Plasmid DNA CDMO Service Product Portfolio
  18. 7.3.5 Biovian Recent Developments
  19. 7.4 GenScript ProBio
  20. 7.4.1 GenScript ProBio Company Information
  21. 7.4.2 GenScript ProBio Business Overview
  22. 7.4.3 GenScript ProBio Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GenScript ProBio Plasmid DNA CDMO Service Product Portfolio
  24. 7.4.5 GenScript ProBio Recent Developments
  25. 7.5 Charles River Laboratories
  26. 7.5.1 Charles River Laboratories Company Information
  27. 7.5.2 Charles River Laboratories Business Overview
  28. 7.5.3 Charles River Laboratories Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Charles River Laboratories Plasmid DNA CDMO Service Product Portfolio
  30. 7.5.5 Charles River Laboratories Recent Developments
  31. 7.6 PackGene
  32. 7.6.1 PackGene Company Information
  33. 7.6.2 PackGene Business Overview
  34. 7.6.3 PackGene Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 PackGene Plasmid DNA CDMO Service Product Portfolio
  36. 7.6.5 PackGene Recent Developments
  37. 7.7 Catalent Biologics
  38. 7.7.1 Catalent Biologics Company Information
  39. 7.7.2 Catalent Biologics Business Overview
  40. 7.7.3 Catalent Biologics Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Catalent Biologics Plasmid DNA CDMO Service Product Portfolio
  42. 7.7.5 Catalent Biologics Recent Developments
  43. 7.8 Patheon
  44. 7.8.1 Patheon Company Information
  45. 7.8.2 Patheon Business Overview
  46. 7.8.3 Patheon Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Patheon Plasmid DNA CDMO Service Product Portfolio
  48. 7.8.5 Patheon Recent Developments
  49. 7.9 Mycenax Biotech Inc
  50. 7.9.1 Mycenax Biotech Inc Company Information
  51. 7.9.2 Mycenax Biotech Inc Business Overview
  52. 7.9.3 Mycenax Biotech Inc Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Mycenax Biotech Inc Plasmid DNA CDMO Service Product Portfolio
  54. 7.9.5 Mycenax Biotech Inc Recent Developments
  55. 7.10 VGXI
  56. 7.10.1 VGXI Company Information
  57. 7.10.2 VGXI Business Overview
  58. 7.10.3 VGXI Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 VGXI Plasmid DNA CDMO Service Product Portfolio
  60. 7.10.5 VGXI Recent Developments
  61. 7.11 Esco Aster
  62. 7.11.1 Esco Aster Company Information
  63. 7.11.2 Esco Aster Business Overview
  64. 7.11.3 Esco Aster Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Esco Aster Plasmid DNA CDMO Service Product Portfolio
  66. 7.11.5 Esco Aster Recent Developments
  67. 7.12 Eurogentec
  68. 7.12.1 Eurogentec Company Information
  69. 7.12.2 Eurogentec Business Overview
  70. 7.12.3 Eurogentec Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Eurogentec Plasmid DNA CDMO Service Product Portfolio
  72. 7.12.5 Eurogentec Recent Developments
  73. 7.13 53Biologics
  74. 7.13.1 53Biologics Company Information
  75. 7.13.2 53Biologics Business Overview
  76. 7.13.3 53Biologics Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  77. 7.13.4 53Biologics Plasmid DNA CDMO Service Product Portfolio
  78. 7.13.5 53Biologics Recent Developments
  79. 7.14 SK pharmteco
  80. 7.14.1 SK pharmteco Company Information
  81. 7.14.2 SK pharmteco Business Overview
  82. 7.14.3 SK pharmteco Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  83. 7.14.4 SK pharmteco Plasmid DNA CDMO Service Product Portfolio
  84. 7.14.5 SK pharmteco Recent Developments
  85. 7.15 Cytovance Biologics
  86. 7.15.1 Cytovance Biologics Company Information
  87. 7.15.2 Cytovance Biologics Business Overview
  88. 7.15.3 Cytovance Biologics Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Cytovance Biologics Plasmid DNA CDMO Service Product Portfolio
  90. 7.15.5 Cytovance Biologics Recent Developments
  91. 7.16 Aldevron
  92. 7.16.1 Aldevron Company Information
  93. 7.16.2 Aldevron Business Overview
  94. 7.16.3 Aldevron Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Aldevron Plasmid DNA CDMO Service Product Portfolio
  96. 7.16.5 Aldevron Recent Developments
  97. 7.17 Bionova Scientific
  98. 7.17.1 Bionova Scientific Company Information
  99. 7.17.2 Bionova Scientific Business Overview
  100. 7.17.3 Bionova Scientific Plasmid DNA CDMO Service Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Bionova Scientific Plasmid DNA CDMO Service Product Portfolio
  102. 7.17.5 Bionova Scientific Recent Developments
8 North America
  1. 8.1 North America Plasmid DNA CDMO Service Revenue (2021-2032)
  2. 8.2 North America Plasmid DNA CDMO Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Plasmid DNA CDMO Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Plasmid DNA CDMO Service Revenue by Type (2027-2032)
  5. 8.3 North America Plasmid DNA CDMO Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Plasmid DNA CDMO Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Plasmid DNA CDMO Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Plasmid DNA CDMO Service Revenue by Application (2027-2032)
  9. 8.5 North America Plasmid DNA CDMO Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Plasmid DNA CDMO Service Revenue by Country
  11. 8.6.1 North America Plasmid DNA CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Plasmid DNA CDMO Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Plasmid DNA CDMO Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Plasmid DNA CDMO Service Revenue (2021-2032)
  2. 9.2 Europe Plasmid DNA CDMO Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Plasmid DNA CDMO Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Plasmid DNA CDMO Service Revenue by Type (2027-2032)
  5. 9.3 Europe Plasmid DNA CDMO Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Plasmid DNA CDMO Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Plasmid DNA CDMO Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Plasmid DNA CDMO Service Revenue by Application (2027-2032)
  9. 9.5 Europe Plasmid DNA CDMO Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Plasmid DNA CDMO Service Revenue by Country
  11. 9.6.1 Europe Plasmid DNA CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Plasmid DNA CDMO Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Plasmid DNA CDMO Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Plasmid DNA CDMO Service Revenue (2021-2032)
  2. 10.2 China Plasmid DNA CDMO Service Revenue by Type (2021-2032)
  3. 10.2.1 China Plasmid DNA CDMO Service Revenue by Type (2021-2026)
  4. 10.2.2 China Plasmid DNA CDMO Service Revenue by Type (2027-2032)
  5. 10.3 China Plasmid DNA CDMO Service Revenue Share by Type (2021-2032)
  6. 10.4 China Plasmid DNA CDMO Service Revenue by Application (2021-2032)
  7. 10.4.1 China Plasmid DNA CDMO Service Revenue by Application (2021-2026)
  8. 10.4.2 China Plasmid DNA CDMO Service Revenue by Application (2027-2032)
  9. 10.5 China Plasmid DNA CDMO Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Plasmid DNA CDMO Service Revenue (2021-2032)
  2. 11.2 Asia Plasmid DNA CDMO Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Plasmid DNA CDMO Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Plasmid DNA CDMO Service Revenue by Type (2027-2032)
  5. 11.3 Asia Plasmid DNA CDMO Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Plasmid DNA CDMO Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Plasmid DNA CDMO Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Plasmid DNA CDMO Service Revenue by Application (2027-2032)
  9. 11.5 Asia Plasmid DNA CDMO Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Plasmid DNA CDMO Service Revenue by Country
  11. 11.6.1 Asia Plasmid DNA CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Plasmid DNA CDMO Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Plasmid DNA CDMO Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Plasmid DNA CDMO Service Revenue (2021-2032)
  2. 12.2 SAMEA Plasmid DNA CDMO Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Plasmid DNA CDMO Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Plasmid DNA CDMO Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Plasmid DNA CDMO Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Plasmid DNA CDMO Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Plasmid DNA CDMO Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Plasmid DNA CDMO Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Plasmid DNA CDMO Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Plasmid DNA CDMO Service Revenue by Country
  11. 12.6.1 SAMEA Plasmid DNA CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Plasmid DNA CDMO Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Plasmid DNA CDMO Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst